S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Enovis Stock Price, News & Analysis (NYSE:ENOV)

$48.74
-2.48 (-4.84%)
(As of 12/5/2023 ET)
Compare
Today's Range
$48.73
$50.58
50-Day Range
$43.67
$52.73
52-Week Range
$43.04
$66.71
Volume
688,139 shs
Average Volume
470,518 shs
Market Capitalization
$2.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.83

Enovis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
39.2% Upside
$67.83 Price Target
Short Interest
Bearish
7.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Enovis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
14.29%
From $2.38 to $2.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

411th out of 948 stocks

Surgical Appliances & Supplies Industry

11th out of 18 stocks


ENOV stock logo

About Enovis Stock (NYSE:ENOV)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

ENOV Stock Price History

ENOV Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Q3 2023 Enovis Corp Earnings Call
Tegna Q3 Earnings Down As Revenues Decline
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
4 Analysts Have This to Say About Enovis
Why Enovis Stock Is Trading Lower Today
See More Headlines
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Employees
6,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$67.83
High Stock Price Target
$75.00
Low Stock Price Target
$62.00
Potential Upside/Downside
+39.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-13,290,000.00
Pretax Margin
-4.66%

Debt

Sales & Book Value

Annual Sales
$1.66 billion
Cash Flow
$6.06 per share
Book Value
$63.71 per share

Miscellaneous

Free Float
51,810,000
Market Cap
$2.66 billion
Optionable
Optionable
Beta
1.98
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report














ENOV Stock Analysis - Frequently Asked Questions

Should I buy or sell Enovis stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings
or view top-rated stocks.

What is Enovis' stock price target for 2024?

5 equities research analysts have issued twelve-month price targets for Enovis' shares. Their ENOV share price targets range from $62.00 to $75.00. On average, they expect the company's stock price to reach $67.83 in the next year. This suggests a possible upside of 39.2% from the stock's current price.
View analysts price targets for ENOV
or view top-rated stocks among Wall Street analysts.

How have ENOV shares performed in 2023?

Enovis' stock was trading at $53.52 at the beginning of the year. Since then, ENOV shares have decreased by 8.9% and is now trading at $48.7350.
View the best growth stocks for 2023 here
.

Are investors shorting Enovis?

Enovis saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,610,000 shares, an increase of 11.4% from the October 15th total of 3,240,000 shares. Based on an average daily volume of 553,400 shares, the days-to-cover ratio is currently 6.5 days. Approximately 7.3% of the company's shares are short sold.
View Enovis' Short Interest
.

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ENOV earnings forecast
.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) posted its earnings results on Tuesday, November, 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.02. The firm had revenue of $417.50 million for the quarter, compared to the consensus estimate of $414.89 million. Enovis had a positive trailing twelve-month return on equity of 3.70% and a negative net margin of 4.51%. Enovis's quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the company posted $0.59 EPS.

What ETFs hold Enovis' stock?
What guidance has Enovis issued on next quarter's earnings?

Enovis issued an update on its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $2.30-2.40 for the period, compared to the consensus EPS estimate of $2.32.

Who are Enovis' major shareholders?

Enovis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Diamond Hill Capital Management Inc. (4.45%), DAVENPORT & Co LLC (3.06%), Channing Capital Management LLC (2.30%), Allspring Global Investments Holdings LLC (1.88%), American Century Companies Inc. (1.59%) and Principal Financial Group Inc. (1.53%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends
.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:ENOV) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -